Evidence map›Paper›PMID 40560862›Full record

ArticlePloS one2025

Establishment of Cre/LoxP-mediated multifunctional reporter knock-in rats with the CRISPR system.

Katsuyuki Nakamura, Sara Ito, Yoshihiro Ohguchi, Toshie Jimbo, Yusaku Wada, Ryota Nakajima, Masanobu Kanou, Kei Yamana, Hiroshi Ueda

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katsuyuki NakamuraDepartment of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University, Gifu, Japan.ORCID 0009-0006-3033-7247
Sara ItoDepartment of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University, Gifu, Japan.
Yoshihiro OhguchiAnimal Management Group Bioscience Business Division, KAC Co., Ltd., Ritto, Shiga, Japan.
Toshie JimboTeijin Ltd., Hino, Tokyo, Japan.
Yusaku WadaResearch and Development Department, FASMAC Co., Ltd., Atsugi, Kanagawa, Japan.
Ryota NakajimaTeijin Ltd., Hino, Tokyo, Japan.
Masanobu KanouTeijin Ltd., Hino, Tokyo, Japan.
Kei YamanaTeijin Ltd., Hino, Tokyo, Japan.ORCID 0009-0009-5242-4300
Hiroshi UedaDepartment of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University, Gifu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rats and mice are essential experimental animals in preclinical research, serving as models for various human diseases and contributing significantly to drug development. Rats offer distinct advantages over mice due to their larger size, which allows for more complex surgical procedures, repeated blood sampling, or sophisticated behavioral analysis. However, unlike the case with mice, genetically modified rat lines for achieving complex experimental objectives-such as tissue-specific gene knockout or visualization of specific cell populations-are still limited. We here established LoxP-mediated multifunctional reporter KI rats, enabling us to evaluate fluorescence, bioluminescence, and cell-killing assays simultaneously with only one gene-modified rat line. CRISPR/Cas12a, also known as CRISPR/Cpf1, was successfully used to insert the Cre sequence into a target locus to generate Cre driver rats. These results will contribute to the application of gene-modified rats for a more comprehensive understanding of physiology, and for extrapolation of their capabilities in preclinical research.

Indexed as

CRISPR-Cas SystemsGene Knock-In TechniquesGenes, ReporterIntegrasesAnimalsMaleRatsRats, TransgenicCre recombinaseIntegrases

Identifiers

PMID40560862
PMCPMC12192107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.